SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-014499
Filing Date
2023-08-10
Accepted
2023-08-10 16:06:07
Documents
88
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ganx-20230630x10q.htm   iXBRL 10-Q 1875286
2 EX-10.3 ganx-20230630xex10d3.htm EX-10.3 119255
3 EX-31.1 ganx-20230630xex31d1.htm EX-31.1 11313
4 EX-31.2 ganx-20230630xex31d2.htm EX-31.2 10526
5 EX-32.1 ganx-20230630xex32d1.htm EX-32.1 10047
  Complete submission text file 0001558370-23-014499.txt   7529876

Data Files

Seq Description Document Type Size
6 EX-101.SCH ganx-20230630.xsd EX-101.SCH 50753
7 EX-101.CAL ganx-20230630_cal.xml EX-101.CAL 60062
8 EX-101.DEF ganx-20230630_def.xml EX-101.DEF 161442
9 EX-101.LAB ganx-20230630_lab.xml EX-101.LAB 462236
10 EX-101.PRE ganx-20230630_pre.xml EX-101.PRE 345061
82 EXTRACTED XBRL INSTANCE DOCUMENT ganx-20230630x10q_htm.xml XML 1171763
Mailing Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814
Business Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814 (301) 500-1556
Gain Therapeutics, Inc. (Filer) CIK: 0001819411 (see all company filings)

IRS No.: 851726310 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40237 | Film No.: 231159301
SIC: 2834 Pharmaceutical Preparations